APYX Stock Overview
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide.
Apyx Medical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.95|
|52 Week High||US$17.50|
|52 Week Low||US$3.01|
|1 Month Change||5.87%|
|3 Month Change||-4.19%|
|1 Year Change||-42.90%|
|3 Year Change||-11.46%|
|5 Year Change||140.89%|
|Change since IPO||81.32%|
Recent News & Updates
Companies Like Apyx Medical (NASDAQ:APYX) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
|APYX||US Medical Equipment||US Market|
Return vs Industry: APYX underperformed the US Medical Equipment industry which returned -23.7% over the past year.
Return vs Market: APYX underperformed the US Market which returned -18.5% over the past year.
|APYX Average Weekly Movement||19.6%|
|Medical Equipment Industry Average Movement||10.4%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: APYX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 20% a week.
Volatility Over Time: APYX's weekly volatility has increased from 14% to 20% over the past year.
About the Company
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures.
Apyx Medical Fundamentals Summary
|APYX fundamental statistics|
Is APYX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|APYX income statement (TTM)|
|Cost of Revenue||US$16.41m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.47|
|Net Profit Margin||-30.96%|
How did APYX perform over the long term?See historical performance and comparison
Is APYX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for APYX?
Other financial metrics that can be useful for relative valuation.
|What is APYX's n/a Ratio?|
Price to Sales Ratio vs Peers
How does APYX's PS Ratio compare to its peers?
|APYX PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: APYX is good value based on its Price-To-Sales Ratio (3.9x) compared to the peer average (6.3x).
Price to Earnings Ratio vs Industry
How does APYX's PE Ratio compare vs other companies in the U.S. Medical Equipment Industry?
Price-To-Sales vs Industry: APYX is expensive based on its Price-To-Sales Ratio (3.9x) compared to the US Medical Equipment industry average (3.9x)
Price to Sales Ratio vs Fair Ratio
What is APYX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||3.9x|
|Fair PS Ratio||7.2x|
Price-To-Sales vs Fair Ratio: APYX is good value based on its Price-To-Sales Ratio (3.9x) compared to the estimated Fair Price-To-Sales Ratio (7.2x).
Share Price vs Fair Value
What is the Fair Price of APYX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate APYX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate APYX's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate APYX's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Apyx Medical forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APYX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: APYX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: APYX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: APYX's revenue (28.8% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: APYX's revenue (28.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if APYX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Apyx Medical performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: APYX is currently unprofitable.
Growing Profit Margin: APYX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: APYX is unprofitable, and losses have increased over the past 5 years at a rate of 4.8% per year.
Accelerating Growth: Unable to compare APYX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APYX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: APYX has a negative Return on Equity (-32.63%), as it is currently unprofitable.
Discover strong past performing companies
How is Apyx Medical's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: APYX's short term assets ($54.8M) exceed its short term liabilities ($11.6M).
Long Term Liabilities: APYX's short term assets ($54.8M) exceed its long term liabilities ($1.6M).
Debt to Equity History and Analysis
Debt Level: APYX is debt free.
Reducing Debt: APYX has no debt compared to 5 years ago when its debt to equity ratio was 12.2%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APYX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: APYX has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 20.7% each year.
Discover healthy companies
What is Apyx Medical current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate APYX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate APYX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if APYX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if APYX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as APYX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Charlie Goodwin (55 yo)
Mr. Charles D. Goodwin II, also known as Charlie, has been Chief Executive Officer and Director of Apyx Medical Corporation (formerly known as Bovie Medical Corporation) since December 15, 2017 and serves...
CEO Compensation Analysis
Compensation vs Market: Charlie's total compensation ($USD1.59M) is about average for companies of similar size in the US market ($USD1.72M).
Compensation vs Earnings: Charlie's compensation has been consistent with company performance over the past year.
Experienced Management: APYX's management team is considered experienced (4 years average tenure).
Experienced Board: APYX's board of directors are considered experienced (5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Apyx Medical Corporation's employee growth, exchange listings and data sources
- Name: Apyx Medical Corporation
- Ticker: APYX
- Exchange: NasdaqGS
- Founded: 1982
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$205.115m
- Shares outstanding: 34.47m
- Website: https://www.apyxmedical.com
Number of Employees
- Apyx Medical Corporation
- 5115 Ulmerton Road
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.